Alvogen today announced the launch of the first generic equivalent of Revlimid™ (lenalidomide) in several CEE markets including Romania, Croatia, Bulgaria and the Baltic states. The product will be marketed as 2.5, 5, 7.5, 10, 15, 20, 25mg hard capsules and is a fully generic and bioequivalent product to Revlimid™. Following the launch into multiple CEE countries, Alvogen’s Lenalidomide will also be launched in selected Asian countries in 2019.
Alvogen’s Lenalidomide has been developed fully in-house at Alvogen‘s subsidiary, Lotus Pharmaceuticals and is part of a comprehensive oncology pipeline.
Revlimid™ is indicated for several hematological malignancies including multiple myeloma and is the biggest-selling oncology drug with approximately $9.8 billion sales globally.
Revlimid™ is a trademark of Celgene Corporation